A plan by Poolbeg Pharma, the clinical-stage biopharmaceutical company led by serial entrepreneur Cathal Friel , to merge with Nasdaq-listed peer Hookipa Pharma has secured backing from a major shareholder in the target company.
Irish-based, but London-listed, Poolbeg said on Tuesday that US biopharma giant Gilead, which owns 19.4 per cent of Hookipa, plans to support a merger if an agreement between both companies is reached. A planned $30 million equity raise immediately after the tie-up would dilute the stakes of legacy investors in both. Poolbeg’s shareholders holding in the combined entity may fall to about 40 per cent as a result, both companies said last week.Shares in Hookipa, where Irish life sciences industry veteran Julie O’Neill is chairperson, slumped by almost 76 per cent in 2023 as the company went through senior management changes and announced three rounds of large job cuts.
الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: IrishTimes - 🏆 3. / 98 اقرأ أكثر »